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Abstract 
Purpose: Central serous chorioretinopathy (CSCR) manifests as neurosensory 
detachment of the macula and can be attributed to focal or multifocal leakage in the 
retinal pigment epithelium (RPE). Fibrin accumulation in the subretinal space is an 
unusual and heretofore unreported visually damaging manifestation of severe CSCR.  
Methods: The patient was followed up with the use of biomicroscopy, fluorescein 
angiography, and optical coherence tomography (OCT).  
Results: A 32-year-old woman was referred to our department complaining of 
metamorphopsia and decreased visual acuity in the right eye. Best-corrected visual 
acuity (BCVA) was 20/40 in the right eye and 20/20 in the left eye. Biomicroscopy 
revealed an irregularly shaped foveal elevation and wrinkling in the right eye. OCT 
showed a steep neurosensory retina elevation with a highly reflective material 
accumulation in the subretinal space, presumably fibrin. Our diagnosis was CSCR 
complicated by subretinal fibrin accumulation. Since most of these cases resolve 
spontaneously, the patient was kept under observation; 1 month later, the fibrin 
accumulation had expanded subfoveally (BCVA 20/200). The patient was offered 3 
intravitreal ranibizumab injections. After the initial injection, BCVA improved to 20/50 
and, after the 3 injections, to 20/30. Two months later (BCVA 20/30), fresh leakage was 
observed at the margin of the original lesion, and an additional intravitreal ranibizumab 
injection was performed. After another 2 months, BCVA stabilized at 20/25 and remained 
stable throughout the 12 months after the initial injection.   
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Conclusions: Prompt recognition of CSCR complicated by subretinal fibrin and 
immediate intervention may result in recovery from this potentially devastating 
complication. Ranibizumab may be an alternative treatment option in the management 
of refractory CSCR complicated by subretinal fibrin accumulation. 
 
Introduction 
Central serous chorioretinopathy (CSCR) manifests as neurosensory detachment of 
the macula and can be attributed to focal or multifocal leakage in the retinal pigment 
epithelium (RPE) [1]. While described as a disease of healthy, type-A personality men, it 
has also been reported in women [2], and is associated with pregnancy. It typically 
develops in the third trimester and resolves spontaneously within 1–2 months after 
delivery [2]. 
Fibrin accumulation in the subretinal space is an unusual visually damaging 
manifestation of severe CSCR [1–3]. Schatz et al. [3], reported 6 cases (average age 40 
years) with CSCR containing fibrin in the subretinal space that later developed into a 
subretinal fibrotic scar, with subsequent subretinal fibrosis and severe visual loss (20/400 
or worse). 
In this case report, we present the rapid and impressive response to ranibizumab in a 
case of CSCR complicated by accumulation of subretinal fibrin. 
Case Report 
A 32-year-old woman was referred to our department complaining of metamorphopsia and decrease 
of visual acuity in the right eye. She reported ongoing significant marital problems and a pregnancy 
during the previous 18 months. Best-corrected visual acuity (BCVA) was 20/40 and 20/20 in the right 
and left eye, respectively. Dilated fundus examination revealed an irregularly shaped foveal elevation 
and wrinkling. In addition, fluorescein angiography (FA) showed partial dye masking in the affected 
area during the early phase followed by ink-blot leakage and subsequent pooling in the superior margin, 
not involving the fovea (fig. 1). In the left eye, we observed old window defects and two small RPE 
detachments. Indocyanine green angiography revealed no signs of neovascularization or polyp-like 
vascular abnormalities. Optical coherence tomography (OCT) showed a serous elevation of the retina 
and a shallow RPE detachment, with subretinal accumulation of highly reflective material (presumably 
fibrin). 
Our initial diagnostic approach was to follow up the patient keeping in mind that this was a case of 
CSCR complicated by fibrin deposition in the subretinal space. 
After 1 month, BCVA decreased to 20/200 and the OCT revealed a more irregular subretinal 
accumulation of highly reflective material that was now involving the fovea (fig. 2). The patient was 
treated with 3 courses of intravitreal ranibizumab injections. After the first injection, BCVA improved 
to 20/50 while the FA leakage had nearly diminished. OCT revealed a slight neurosensory retina 
elevation without any apparent subretinal exudation (fig. 3). Two more intravitreal ranibizumab 
injections were repeated at monthly intervals. Two months later, visual acuity was 20/30, while 
metamorphopsia was still persisting. During the follow-up period, a new leakage area was observed at 
the margin of the original lesion. One more intravitreal ranibizumab injection was offered. In the 
following 2 months, BCVA stabilized at 20/25 and remained stable for the following 12 months, without 
any apparent significant FA leakage (fig. 1).  
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Discussion 
The presence of fibrin with spontaneous resolution in the majority of CSCR cases has 
been previously reported [1]. Subretinal fibrin and other extracellular matrix molecules 
appear to stimulate the RPE to undergo fibrous metaplasia, which results in subretinal 
fibrotic scar formation and other sequelae, all of which can lead to severe visual loss [3]. 
In our patient, a steep neurosensory retinal elevation with an extrafoveal subretinal 
deposition of a fibrin-like material was observed several months after delivery. 
Subsequent fibrinolysis of this meshwork resulted in an amorphous, homogenous 
subretinal accumulation with involvement of the fovea and significant reduction of the 
visual acuity. Due to the presence of subfoveal fluid, we decided to offer a 3-injection 
course of intravitreal ranibizumab which resulted in rapid subretinal material (fibrin) 
absorption and improvement of both BCVA and foveal contour confirmed by OCT. 
According to the literature [1, 2], in the majority of relevant cases, there is gradual 
resolution of this fibrin-like material accumulation as a result of a resumption of normal 
RPE function (in pregnant women, in particular it, resolves spontaneously within 1–2 
months after delivery). Schatz et al. [3], reported 6 cases (average age 40 years) with CSCR 
containing fibrin in the subretinal space which developed into a subretinal fibrotic scar. 
Scar formation was followed by a tenting up of the macula, vascularization of the fibrosis 
(subretinal neovascularization), or a retinal pigment epithelial rip. Four of the 7 eyes with 
subretinal fibrosis had severe visual loss (20/400 or worse). 
Ranibizumab has been reported to be an effective treatment of choroidal 
neovascularization related to chronic CSCR. However, residual intraretinal or subretinal 
fluid in addition to increased choroidal permeability persisted in a small case series [4]. 
Ranibizumab has been shown to have no significant direct effect on the choriocapillaris in 
animal models [5]. Conversely, recent evidence from in vitro studies suggests that 
ranibizumab may decrease RPE barrier function by temporarily enhancing RPE 
permeability for a small number of days [6]. In this case, it is not clear whether 
intravitreal ranibizumab contributed to the dissolution of the fibrin-like material, and it is 
conceivable that resolution may have occurred without any intervention. In contrast, the 
rapid response to ranibizumab may suggest that this anti-VEGF agent may be an 
alternative treatment option in the management of refractory CSCR complicated by 
subretinal fibrin accumulation. Further experimental studies investigating the potential 
anti-VEGF effect on modulating RPE function (e.g. ion pump activation) are required to 
validate this hypothesis. 
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Fig. 1. Subretinal deposition of a fibrin-like material in the right eye at baseline visit: a Red-free photo; 
b FA during the early phase (15 s); c FA during the late phase (8 min and 51 s), and d OCT scans 
depicting a steep neurosensory retinal elevation and a shallow RPE detachment with an accumulation 
of a fibrin-like material with high reflectivity. 
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Fig. 2. a Red-free photo; b FA during the early phase (16 s); c FA during the late phase (17 min and  
09 s), showing macular involvement, and d OCT scan of the first follow-up performed after treatment 
discontinuation. Fibrinolysis of the fibrin-like meshwork resulted in an amorphous, homogenous 
subretinal accumulation with involvement of the fovea. 
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Fig. 3. a FA during the early phase (15 s); b FA during the late phase (7 min and 09 s); c OCT 4 weeks 
after the first ranibizumab injection revealing a small quantity of subretinal fluid but no fibrin-like 
accumulation; d FA during the early phase (16 s); e FA during the late phase (7 min and 40 s) showing 
localized fibrosis and, and f OCT 4 weeks after the fourth ranibizumab injection showing absence of 
subretinal fluid. 
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